Palbociclib , ≥99% , 571190-30-2

Synonym(s):
6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one;Ibrance

CAS NO.：571190-30-2

Empirical Formula: C24H29N7O2

Molecular Weight: 447.53

MDL number: MFCD11840850

EINECS: 810-186-2

PRODUCT Properties

• Melting point: 200 ºC
• Boiling point: 711.5±70.0 °C(Predicted)
• Density: 1.313±0.06 g/cm3(Predicted)
• storage temp.: room temp
• solubility: Soluble in DMSO (up to 2 mg/ml with warming)
• pka: 8.66±0.10(Predicted)
• form: powder
• color: white to beige
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.

Description and Uses

Palbociclib is a cyclin-dependent kinase (CDK) 4 and CDK6 inhibitor approved by the FDA to treat hormone receptor-positive (HR+) human epidural growth factor 2-negative (HER2-) metastatic breast cancer. It is used in combination with letrazole as the first-line hormonal-based therapy in postmenopausal women, or with fulvestrant in women with disease progression following hormonal therapy. Palbociclib was discovered at Warner- Lambert and developed by Pfizer after their merger. Pfizer is also studying the effectiveness of palbociclib in a variety of other cancers at various stages in the clinic.

Palbociclib (also known as compound number PD-0332991) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.

Safety

• Symbol(GHS): GHS08,GHS09
• Signal word: Warning
• Hazard statements: H341-H361f-H373-H411
• Precautionary statements: P201-P202-P260-P273-P280-P308+P313